Title TBD

Byron C Jaeger, PhD1

1Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC.

Table 1: Participant characteristics.

| **Characteristic1** | **Overall, N = 1230 (100%)** | **Normal blood pressure, N = 613 (50%)** | **Elevated blood pressure, N = 225 (18%)** | **Stage 1 hypertension, N = 392 (32%)** |
| --- | --- | --- | --- | --- |
| Age, years | 46 (7) | 45 (7) | 47 (7) | 47 (7) |
| Sex |  |  |  |  |
| Women | 60 | 67 | 62 | 49 |
| Men | 40 | 33 | 38 | 51 |
| Body mass index, kg/m2 | 31.0 (7.0) | 30.3 (7.0) | 31.2 (6.7) | 31.8 (7.0) |
| Currently smoking | 14 | 12 | 17 | 15 |
| Statin use | 3.3 | 3.1 | 3.6 | 3.6 |
| Systolic blood pressure, mm Hg | 118 (10) | 110 (6) | 124 (3) | 128 (7) |
| Diastolic blood pressure, mm Hg | 75 (7) | 71 (6) | 74 (4) | 82 (5) |
| Diabetes | 5.9 | 3.9 | 8.4 | 7.4 |
| Total cholesterol, mg/dL | 196 (35) | 194 (32) | 195 (37) | 201 (36) |
| High density lipoprotein cholesterol, mg/dL | 51 (13) | 51 (13) | 51 (13) | 50 (13) |
| Low density lipoprotein cholesterol, mg/dL | 127 (33) | 126 (32) | 125 (34) | 131 (34) |
| PREVENT 10-year CVD risk, % | 2.4 (2.1) | 1.8 (1.6) | 2.8 (2.2) | 3.2 (2.4) |
| PREVENT 30-year CVD risk, % | 14.0 (8.1) | 11.3 (6.9) | 15.7 (7.9) | 17.4 (8.5) |
| Hypertension at visit 3 | 46 | 29 | 54 | 67 |
| Left ventricular mass at visit 3, g/m2.7 | 31 (7) | 30 (7) | 31 (6) | 32 (7) |
| Left ventricular hypertrophy at visit 3 | 5.9 | 6.1 | 4.3 | 6.5 |
| 1Table values are mean (standard deviation) or percent | | | | |
| Abbreviations: CVD = cardiovascular disease; and PREVENT = predicting risk of cardiovascular disease events | | | | |

Table 2: Distribution of PREVENT 10- and 30-year predicted risk for cardiovascular disease.

| **PREVENT CVD risk** | | **Blood pressure category** | | | |
| --- | --- | --- | --- | --- | --- |
| **10-year** | **30-year** | **Overall** | **Normal blood pressure** | **Elevated blood pressure** | **Stage 1 hypertension** |
| N (%) of participants | | | | | |
| < 10% | <10% | 457 (38) | 316 (52) | 58 (26) | 83 (22) |
| 10% to <15% | 288 (24) | 141 (23) | 60 (27) | 87 (23) |
| 15% to <20% | 207 (17) | 72 (12) | 50 (23) | 85 (22) |
| 20% to <25% | 155 (13) | 61 (10) | 28 (13) | 66 (17) |
| 25% to <30% | 69 (5.7) | 13 (2.1) | 16 (7.2) | 40 (10) |
| ≥30% | 39 (3.2) | 8 (1.3) | 9 (4.1) | 22 (5.7) |
| ≥ 10% | ≥30% | 15 (100) | 2 (100) | 4 (100) | 9 (100) |
| % with hypertension at visit 2 or visit 3 | | | | | |
| < 10% | <10% | 43 | 32 | 54 | 73 |
| 10% to <15% | 51 | 34 | 48 | 78 |
| 15% to <20% | 63 | 41 | 73 | 76 |
| 20% to <25% | 62 | 39 | 82 | 74 |
| 25% to <30% | 61 | 31 | 53 | 74 |
| ≥30% | 89 | 71 | 89 | 95 |
| ≥ 10% | ≥30% | 87 | 50 | 100 | 89 |
| LV mass mean (% with LV hypertrophy) at visit 3 | | | | | |
| < 10% | <10% | 30 (6.5) | 30 (6.8) | 31 (0.00) | 32 (9.4) |
| 10% to <15% | 30 (3.8) | 30 (1.7) | 28 (3.4) | 32 (7.0) |
| 15% to <20% | 31 (6.7) | 29 (6.5) | 30 (0.00) | 33 (10) |
| 20% to <25% | 32 (8.3) | 31 (10) | 36 (17) | 32 (0.00) |
| 25% to <30% | 32 (5.4) | 29 (0.00) | 35 (14) | 31 (4.5) |
| ≥30% | 34 (6.7) | 38 (25) | 26 (0.00) | 34 (0.00) |
| ≥ 10% | ≥30% | 33 (0.00) | 33 (0.00) | -- (--) | 32 (0.00) |

Table S1: Exclusions

| **Inclusion criteria** | **No. of participants** |
| --- | --- |
| JHS participants | 5,306 |
| Age 30 to < 60 years at visit 1 | 3,067 |
| Consented to CVD follow-up at visit 1 | 2,953 |
| No history of CVD at visit 1 | 2,943 |
| Have information on self-reported antihypertensive medication use and blood pressure at visit 1 | 2,882 |
| Have information on other variables in the PCEs and PREVENT equations at visit 1 | 2,608 |
| All variables in range for PREVENT equations at visit 1 | 2,489 |
| Without hypertension at visit 1 | 1,388 |
| With hypertension status known at visit 2 or visit 3 | 1,230 |